Physician profile
Benjamin C Leslie
NPI 1902165228
$4,717.30
in general payments reported to CMS, 2019-2025
30 companies · $604 in 2025
The $604 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $490 · 2021: $725 · 2022: $859 · 2023: $892 · 2024: $661 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143 · Education: $14.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.60 |
| Education | $14.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $821.45 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $715.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $461.75 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $387.22 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $288.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $275.05 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.65 | 2020-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $266.05 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $248.58 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $244.58 | 2021-2024 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $117.75 | 2024-2025 | Voquezna |
| Pfizer INC. | $114.18 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $58.19 | 2019-2021 | |
| Dexcom, INC. | $55.88 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $50.05 | 2023-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.91 | 2023-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $41.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.81 | 2022 | |
| Glaxosmithkline, LLC. | $30.96 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $28.40 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.40 | 2024 | Lifevest |
| Allergan, INC. | $21.08 | 2020 | |
| Abbott Laboratories | $16.91 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $16.19 | 2025 | Vyepti |
| Xeris Pharmaceuticals, INC. | $16.04 | 2023 | Gvoke Hypopen |
| Mylan Specialty L.P. | $15.36 | 2021 | |
| Corcept Therapeutics | $14.65 | 2020 | |
| Philips North America LLC | $13.95 | 2019 | |
| Heartflow, INC. | $13.55 | 2024 | |
| Alkermes, INC. | $13.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Leslie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.